Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 621 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Subutex Clear all
Completed Phase 2 Interventional

Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans

NCT04360681
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Opioid-use Disorder
Interventions
Lofexidine, Placebo oral tablet
Drug
Lead sponsor
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Other
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 29, 2026, 5:11 PM EDT
Completed Phase 2 Interventional Results available

Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals

NCT01262092
View directory record Official record
Conditions
Opioid Dependence, Opioid Withdrawal, Opioid Detoxification
Interventions
Buprenorphine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 29, 2026, 5:11 PM EDT
Completed Phase 2 Interventional

Effective Treatment for Prescription Opioid Abuse

NCT00719095
View directory record Official record
Conditions
Prescription Opioid Dependence
Interventions
buprenorphine taper followed by naltrexone maintenance, Behavioral therapy
Drug · Behavioral
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Oct 29, 2026, 5:11 PM EDT
Recruiting Phase 4 Interventional

BUprenorphine Versus Morphine for Postcesarean Analgesia (BUMP)

NCT07786012
View directory record Official record
Conditions
Cesarean Delivery
Interventions
buprenorphine, morphine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
19 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 29, 2026, 5:11 PM EDT
Enrolling by invitation Not applicable Interventional

TRTME: Improving Outpatient Initiation of Medication for Opioid Use Disorder Following Hospitalization

NCT07780097
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions
TRTME
Behavioral
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 29, 2026, 5:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Multi-site Intervention to Expand Hospital Based OUD Treatment Provision

NCT06291090
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
OUD treatment intervention
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 29, 2026, 5:11 PM EDT
Completed Phase 2 Interventional

Evaluation of Liquid vs. Tablet Buprenorphine - 6

NCT00000341
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 29, 2026, 5:11 PM EDT
Recruiting No phase listed Observational

Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy

NCT05942313
View directory record Official record
Conditions
Opioid Use Disorder, Pregnancy Related
Interventions
Buprenorphine/ Methadone exposure
Drug
Lead sponsor
Ilana Hull
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 29, 2026, 5:11 PM EDT
Active, not recruiting Not applicable Interventional

Buprenorphine Integration Research and Community Health

NCT05668780
View directory record Official record
Conditions
Opioid Use Disorder, HIV Infections, Hepatitis C
Interventions
NIATx Coaching
Behavioral
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 29, 2026, 5:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers

NCT02479308
View directory record Official record
Conditions
Healthy
Interventions
Moxifloxacin, ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Oct 29, 2026, 5:11 PM EDT
Completed Not applicable Interventional Results available

Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans

NCT01096550
View directory record Official record
Conditions
Drug Dependence
Interventions
Outpatient, Intensive Outpatient
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 85 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 29, 2026, 5:11 PM EDT
Completed Phase 1 Interventional

Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2

NCT00015041
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1998
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 29, 2026, 5:11 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients

NCT01820442
View directory record Official record
Conditions
Opioid Dependence, Buprenorphine Withdrawal Syndrome
Interventions
Lofexidine HCl, Lofexidine-matching sugar pill
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 29, 2026, 5:11 PM EDT
Completed Not applicable Interventional

An Integrated Intervention Involving Recovery Coaching and Cognitive Behavioral Therapy for Opioid Use Disorder

NCT06102200
View directory record Official record
Conditions
Standard of Care, Standard of Care + CBT4CBT, Standard of Care + CBT4CBT + RC
Interventions
CBT4CBT, RC, Sandard of care
Behavioral
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 29, 2026, 5:11 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

NCT00313846
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 75 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
44
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 29, 2026, 5:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Adaptive Dispenser Initiation Protocols for MySafeRx During Post-detox Buprenorphine Treatment- a Pilot Study

NCT04449744
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
MySafeRx Inspire Plus, MySafeRx Inspire Flex
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 29, 2026, 5:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)

NCT00571961
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra (lopinavir/ritonavir), buprenorphine, Clinical evaluations/Blood draws
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Oct 29, 2026, 5:11 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial

NCT00684554
View directory record Official record
Conditions
Opioid-Related Disorders, Heroin Dependence
Interventions
Buprenorphine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 29, 2026, 5:11 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals

NCT01136356
View directory record Official record
Conditions
Opioid Abuse, Opioid Dependence
Interventions
buprenorphine, morphine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 29, 2026, 5:11 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain

NCT06442566
View directory record Official record
Conditions
Opioid Withdrawal, Chronic Pain
Interventions
Buprenorphine Patch, Placebo, Transcranial Magnetic Stimulation (TMS), Sham Transcranial Magnetic Stimulation (TMS)
Drug · Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 29, 2026, 5:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Brief Negotiation Interview Chatbot to Improve Buprenorphine Engagement Among Justice-Involved Individuals

NCT04982627
View directory record Official record
Conditions
Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Criminal Behavior
Interventions
BNI Chatbot, OUD Education & Treatment Resources
Behavioral
Lead sponsor
Center for Progressive Recovery, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 29, 2026, 5:11 PM EDT
Terminated Phase 2 Interventional

Abuse Potential of Buprenorphine/Naloxone

NCT00149539
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 29, 2026, 5:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions

NCT01157169
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 29, 2026, 5:11 PM EDT
Withdrawn Phase 4 Interventional

Suboxone User Perioperative Early Referral and Enhanced Recovery After Surgery- Orthopaedic Trauma Surgery Population

NCT04464512
View directory record Official record
Conditions
Addiction Opiate, Chronic Pain, Fractures, Bone, Buprenorphine Dependence
Interventions
Sufentanil
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 29, 2026, 5:11 PM EDT